Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have received a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $16.8333.

Several research firms have issued reports on ALT. B. Riley dropped their price target on shares of Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Altimmune in a research note on Monday. UBS Group dropped their target price on shares of Altimmune from $26.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Monday, October 20th.

Institutional Investors Weigh In On Altimmune

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after purchasing an additional 1,206,514 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Altimmune by 356.6% in the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after purchasing an additional 1,559,562 shares during the period. Geode Capital Management LLC lifted its stake in shares of Altimmune by 13.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock worth $7,489,000 after buying an additional 228,995 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Altimmune by 387.7% during the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock worth $3,543,000 after buying an additional 727,731 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Altimmune by 155.2% during the 2nd quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock worth $2,771,000 after buying an additional 435,467 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Up 0.6%

ALT stock opened at $5.17 on Friday. The company has a market cap of $539.45 million, a price-to-earnings ratio of -4.38 and a beta of 0.01. Altimmune has a twelve month low of $2.90 and a twelve month high of $10.88. The business has a 50 day moving average price of $4.12 and a two-hundred day moving average price of $4.47. The company has a quick ratio of 20.44, a current ratio of 20.44 and a debt-to-equity ratio of 0.09.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Analysts anticipate that Altimmune will post -1.35 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.